Horita A, Nair X, Hamilton A E
Science. 1972 May 26;176(4037):931-2. doi: 10.1126/science.176.4037.931.
In rats previously treated with a monoamine oxidase inhibitor, the administration of 5-hydroxytryptophan results in increases in concentrations of 5-hydroxytryptamine in kidney, brain, and adrenal glands. When the peripheral L-aromatic amino acid decarboxylase inhibitor, L-alpha-methyl-alpha-hydrazino-beta-(3,4-dihydroxyphenyl)propionic acid (HMD) is administered prior to 5-hydroxytryptophan, the concentration of 5-hydroxytryptamine in kidneys does not rise, that of the brain increases slightly, and that of the adrenal rises markedly. This indicates that although the adrenal gland is a peripheral organ, it does not respond in the typical manner to the antidecarboxylase action of HMD. These results suggest that HMD does not gain free access into the adrenal medulla and that a possible "blood-adrenal barrier" may exist to this compound.
在先前用单胺氧化酶抑制剂处理过的大鼠中，给予5-羟色氨酸会导致肾脏、大脑和肾上腺中5-羟色胺浓度升高。当在给予5-羟色氨酸之前先给予外周L-芳香族氨基酸脱羧酶抑制剂L-α-甲基-α-肼基-β-(3,4-二羟基苯基)丙酸（HMD）时，肾脏中5-羟色胺的浓度不会升高，大脑中的浓度略有增加，而肾上腺中的浓度则显著升高。这表明，尽管肾上腺是外周器官，但它对HMD的抗脱羧酶作用没有典型反应。这些结果表明，HMD无法自由进入肾上腺髓质，并且可能存在针对该化合物的“血-肾上腺屏障”。
